hVIVO PLC (AIM:HVO), the clinical development company specialising in human challenge trials, has signed a consultancy contract with Decoy Therapeutics to support the development of a novel class of broad-spectrum respiratory antivirals. The engagement covers translational modelling, regulatory strategy, chemistry, manufacturing and controls consulting, non-clinical development support, and preparation of clinical and regulatory documentation for submissions to European and UK regulators, including the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency.